Efficacy and safety of tolvaptan in heart failure patients with sustained volume overload despite the use of conventional diuretics: A phase III open-label study

Cardiovascular Drugs and Therapy

Volumn 25, Issue SUPPL. 1, 2011, Pages

  Fukunami, Masatake ^a   Matsuzaki, Masunori ^b   Hori, Masatsugu ^c   Izumi, Tohru ^d  

^a OSAKA GENERAL MEDICAL CENTER   (Japan)

^b YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^d KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Aquaretic effect; Heart failure; Tolvaptan; Vasopressin V2 receptor; Volume overload

Indexed keywords

ALDOSTERONE ANTAGONIST; FUROSEMIDE; LOOP DIURETIC AGENT; THIAZIDE DIURETIC AGENT; TOLVAPTAN;

ADULT; AGED; ARTICLE; BRAIN EMBOLISM; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE ASSOCIATION; DIURETIC THERAPY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; FLUID RETENTION; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART VENTRICLE OVERLOAD; HEART VENTRICLE TACHYCARDIA; HEPATOMEGALY; HUMAN; HYPONATREMIA; JAPANESE; KIDNEY FAILURE; LEG EDEMA; LUNG CONGESTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; POLLAKISURIA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; THIRST; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL; URINE VOLUME; VEIN DILATATION; WEIGHT REDUCTION;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BENZAZEPINES; BLOOD UREA NITROGEN; BODY WEIGHT; CREATININE; DIURETICS; EDEMA, CARDIAC; FEMALE; HEART FAILURE; HUMANS; MALE; POTASSIUM; RECEPTORS, VASOPRESSIN; SODIUM;

EID: 83655183726     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-011-6348-y     Document Type: Article

References (12)

1. Japanese Circulation Society. Guidelines for the diagnosis and treatment of cardiovascular disease (Joint Study Group Report 2009): guidelines for treatment of chronic heart failure (revised 2010). http://www.j-circ.or.jp/ guideline/pdf/JCS2010-matsuzaki-h.pdf. Accessed 13 April 2011.
2. A Nohria SW Tsang JC Fang, et al. 2003 Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure J Am Coll Cardiol 41 1797 1804 12767667 10.1016/S0735-1097(03)00309-7 (Pubitemid 36584255)
3. EB Raftery 1994 Haemodynamic effects of diuretics in heart failure Br Heart J 72 suppl S44 S47 7946758 10.1136/hrt.72.2-Suppl.S44 1:STN:280: DyaK2M%2FjtlKruw%3D%3D (Pubitemid 24249727)
4. I Anand VG Florea 2001 Diuretics in chronic heart failure-benefits and hazards Eur Heart J Suppl 3 Suppl G G8 G18 1:CAS:528:DC%2BD3MXmtVKru78%3D (Pubitemid 32702963)
5. S Gupta L Neyses 2005 Diuretic usage in heart failure: a continuing conundrum in 2005 Eur Heart J 26 644 649 15734765 10.1093/eurheartj/ehi176 1:CAS:528:DC%2BD2MXksFGnsrg%3D (Pubitemid 40516875)
6. SA Hunt WT Abraham MH Chin, et al. 2005 ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society Circulation 112 e154 e235 16160202 10.1161/CIRCULATIONAHA.105.167586
7. Y Yamamura S Nakamura S Itoh, et al. 1998 OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats J Pharmacol Exp Ther 287 860 867 9864265 1:CAS:528:DyaK1MXjvVShsw%3D%3D (Pubitemid 29131593)
8. M Gheorghiade I Niazi J Ouyang, et al. 2003 Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial Circulation 107 2690 2696 12742979 10.1161/01.CIR.0000070422.41439.04 1:CAS:528:DC%2BD3sXjvFKjtbk%3D (Pubitemid 36667242)
9. LC Costello-Boerrigter WB Smith G Boerrigter, et al. 2006 Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure Am J Physiol Renal Physiol 290 F273 F278 16189291 10.1152/ajprenal.00195.2005 1:CAS:528:DC%2BD28XhsFKit7Y%3D (Pubitemid 43724981)
10. K Okita I Sakaida M Okada, et al. 2010 A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis J Gastroenterol 45 979 987 20387081 10.1007/s00535-010-0240-6 1:CAS:528: DC%2BC3cXhtFGhtrnO
11. Matsuzaki M, Masatsugu H, Izumi T, Asanoi H, Tsutamoto T, Tolvaptan Investigators. Effects of tolvaptan on volume overload in Japanese patients with heart failure: results of a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Cardiovasc Drugs Ther. 2011; e-pub ahead of print.
12. Matsuzaki M, Fukunami M, Hori M, Izumi T, Tolvaptan Investigators. Efficacy and safety of tolvaptan in heart failure patients with excessive fluid retention following treatment with other diuretics: a phase iii, randomized, double-blinded and placebo-controlled study (The QUEST study). Cardiovasc Drugs Ther. 2011; e-pub ahead of print.